UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 12b-25

NOTIFICATION OF LATE FILING


(Check One)  [X]  Form 10-K  [   ]  Form 20-F  [   ]  Form 11-K  [   ]  Form 10-Q  [   ]  Form 10-D  [   ]  Form N-SAR  [   ]  Form N-CSR

For Period Ended:   December 31, 2007
 
[   ] Transition Report on Form 10-K
[   ] Transition Report on Form 20-F
[   ] Transition Report on Form 11-K
[   ] Transition Report on Form 10-Q
[   ] Transition Report on Form N-SAR
 
For the Transition Period Ended:

Read Instruction (on back page) Before Preparing Form.  Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Integrated Pharmaceuticals, Inc.  
Full Name of Registrant
 
 
N/A  
Former Name if Applicable
 
 
310 Authority Drive  
Address of Principal Executive Office (Street and Number)
 
 
Fitchburg, MA 01420-6047
City, State and Zip Code


 
 
 
 
PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate)
 
 
  x
(a)  The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c)  The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
 

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report, or portion thereof, could not be filed within the prescribed time period.

The Registrant is not able to file its Form 10-KSB for the period ended December 31, 2007 on the date required.  The Registrant is in the process of preparing and reviewing the financial information and compiling and disseminating the information required to be included in the Form 10-KSB for the period ended December 31, 2007, as well as the completion of the required review of the Company's financial information, none of which could be completed by the date required without incurring undue hardship and expense.  The Registrant expects to file its Form 10-KSB within the 15 calendar days provided by this extension.

PART IV - OTHER INFORMATION

(1)  Name and telephone number of person to contact in regard to this notification
 
Peter Featherston                
(978) 696-0020 
(Name)     
(Area Code)(Telephone Number) 
 
(2)  Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If answer is no, identify report(s).

[X]  Yes   [   ]  No

(3)  Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the
subject report or portion thereof?
 
[   ]  Yes   [X]  No

 
 
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
Integrated Pharmaceuticals, Inc.
(Name of Registrant as Specified in Charter) 
 
Integrated Pharmaceuticals, Inc.
 
Integrated Pharmaceuticals, Inc.
(Name of Registrant as Specified in Charter)

In accordance with section 13 or 15(d) of the Exchange Act, the registrant has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 28, 2008

 
By:  /s/ Peter Featherston 
  Peter Featherston 
  Chief Executive Officer
 

 
INSTRUCTION:  The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature.  If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

 
 
 

Integrated Pharmaceuticals (CE) (USOTC:INTP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Integrated Pharmaceuticals (CE) Charts.
Integrated Pharmaceuticals (CE) (USOTC:INTP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Integrated Pharmaceuticals (CE) Charts.